Longeveron
About:
Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.
Website: http://longeveron.com
Top Investors: TEDCO, National Institutes of Health, Alzheimer's Association
Description:
Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases. Longeveron's primary investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of healthy adult donors. Lomecel-B™ exhibits various potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects. These properties make it applicable across a range of diseases. Longeveron is currently conducting clinical trials for Lomecel-B™ in three areas: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.
$34M
$1M to $10M
Miami, Florida, United States
2014-01-01
Donald Soffer, Joshua M. Hare
11-50
2024-07-18
Public
© 2025 bioDAO.ai